Correspondence 0001437749-23-016769 from Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: June 6, 2023 · CIK: 0001029125 · Accession: 0001437749-23-016769
AI Filing Summary & Sentiment
File numbers found in text: 333-271729
Letter
pbla20230606_corresp.htm
June 6, 2023
VIA EDGAR TRANSMISSION
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6010
Attn:
Tim Buchmiller
Re:
Panbela Therapeutics, Inc.
Registration Statement on Form S-1 (Registration No. 333-271729)
Request for Acceleration of Effective Date
Ladies and gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-271729) (the “Registration Statement”) to become effective on June 8, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement.
Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.
[Signature Page Follows]
Very truly yours,
PANBELA THERAPEUTICS, INC.
By:
/s/ Susan Horvath
Name:
Susan Horvath
Title:
Chief Financial Officer
Roth Capital Partners, LLC
888 San Clemente Drive, Suite 400
Newport Beach, CA 92660
June 6, 2023
VIA EDGAR CORRESPONDENCE
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Panbela Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-271729
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 4:30 p.m., Eastern time, on Thursday, June 8, 2023, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated June 2, 2023 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
ROTH CAPITAL PARTNERS, LLC
Show Raw Text
CORRESP 1 filename1.htm pbla20230606_corresp.htm June 6, 2023 VIA EDGAR TRANSMISSION Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Attn: Tim Buchmiller Re: Panbela Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-271729) Request for Acceleration of Effective Date Ladies and gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-271729) (the “Registration Statement”) to become effective on June 8, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement. Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946. [Signature Page Follows] Very truly yours, PANBELA THERAPEUTICS, INC. By: /s/ Susan Horvath Name: Susan Horvath Title: Chief Financial Officer Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 June 6, 2023 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Panbela Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-271729 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the placement agent, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 4:30 p.m., Eastern time, on Thursday, June 8, 2023, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated June 2, 2023 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, ROTH CAPITAL PARTNERS, LLC By: /s/ Aaron M. Gurewitz Aaron M. Gurewitz Head of Equity Capital Markets cc: M. Ali Panjwani, Esq. Pryor Cashman LLP